Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Work In Process (2025)

BridgeBio Pharma (BBIO) has disclosed Work In Process for 1 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Work In Process changed N/A to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $6.1 million for FY2025, N/A changed from the prior year.
  • Work In Process hit $6.1 million in Q4 2025 for BridgeBio Pharma, up from $4.1 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.1 million in Q4 2025 to a low of $1.1 million in Q2 2025.